Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Parkinson's Disease Research Studies

Study Title:   An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes, Cynapsus)  (Identifier NCT02542696)

Study Purpose:  A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Study Title:  RESTORE:  A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy. (Identifier NCT02586623)

Study Purpose:  To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH) (dizziness, light-headedness, or feelings that they are about to black out).

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Study Title:   A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P 2B001 Once Daily Compared to Its Individual Components With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.  (Identifier NCT03329508)

Study Purpose:  A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be randomized to 4 treatment groups. Each subject will participate in the study for approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2 weeks follow-up period.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Last Updated: 4/24/19